

No increased rate of SARS-CoV-2 infection for patients with inflammatory rheumatic diseases compared with the general population in the city of Hamburg (Germany)

We highly appreciated the work on the paper by Gianfrancesco *et al.*¹ While this large international registry provides information, for example, about the course of the disease in regard to the intensity of immunosuppression or complications, they do not allow any conclusions about the actual incidence rate of infections in patients with rheumatic diseases compared with the overall population. In addition to the data by Gianfrancesco *et al* we here like to share our data and experience of the Hamburg COVID-19 registry.

Until 9 June 2020, a total of 5120 proven severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections were reported in Hamburg.² This corresponds to 0.28% of the total population of the city of Hamburg (1.814 million inhabitants), with a reported mortality rate of 4.4% (in total 226 patients).

With the beginning of the COVID-19 pandemic we initiated a SARS-CoV-2 registry, where all reported COVID cases were documented anonymously by all rheumatologists of the city of Hamburg. In total, 11 771 patients were prescribed any disease-modifying antirheumatic drug (DMARD) during this period. Of these, a total of 30 (0.25%) patients had a clinically tested SARS-CoV-2 infection (clinical symptoms and SARS-CoV-2 PCR and/or IgG positive). Three out of 30 patients with rheumatic diseases (10%) were treated with severe disease in intensive care unit, in contrast to 4.4% of patients with COVID of the general population. So far, no deaths were reported in our cohort (mortality rate 0%) (see [table 1](#)).

In analogy to the COVID-19 Global Rheumatology Alliance registry, our cohort found no evidence that individual rheumatological diseases lead to a higher risk for or a severe course of infection. Additionally, so far, no accumulation of infection among one of the therapy groups (conventional synthetic DMARD, biological DMARD or targeted synthetic DMARD) was apparent.¹

Table 1 Number of SARS-Cov-2 infections, ICU admissions and death in the general population compared to DMARD treated patients as well as calculated incidences

	General population	DMARD-treated patients with rheumatic diseases
Total, n	1.814.000	10.771
SARS-CoV-2 infected, n (%)	5120 (0.28)	30 (0.25)
ICU, n (%)	227 (4.4)	3 (10)
Death, n (%)	226 (4.4)	0 (0)

DMARD, disease-modifying antirheumatic drug; ICU, intensive care unit; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

To the best of our knowledge, this is the largest population-based study to date in this particular risk group. We consider the risk of unreported cases for the group of the general population comparable with that for the patients with rheumatic diseases.

In summary, patients with rheumatic diseases and under DMARD therapy do not seem to have a higher risk of a SARS-CoV-2 infection.

Additionally, in this cohort patients with rheumatic diseases did not have a higher rate of a severe course of SARS-CoV-2 infection.

Peer Aries,¹ Christof Iking-Konert²

¹Rheumatologie und klinische Immunologie, Rheumatologie im Struenseehaus, Hamburg, Germany

²Nephrology and Rheumatology, Department of Medicine III, University of Hamburg Faculty of Medicine, Hamburg, Germany

Correspondence to Dr Christof Iking-Konert, Nephrology and Rheumatology, Department of Medicine III, University of Hamburg Faculty of Medicine, Hamburg 20146, Germany; c.iking-konert@uke.de

Acknowledgements We would like to thank all rheumatologists of the Rheumazentrum Hamburg who participated in the register.

Collaborators K Ahmadi, A von Alt Stutterheim, E Barth, H Bisinger, P Bremer, S El-Nawab-Becker, A Gödde, H Heintz, M Janneck, S Kahl, M Kern, B Panzer, C Platzeck, L Roth, M Schaposchnikow, A Schiewek-Güsmer, U Schnoor, S Tatzis, H Tremel, B. Varoga, J. Veigel, W. Winter, J Wollenhaupt.

Contributors Both authors contributed equally in collecting and analysing the data as well as in writing the manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; internally peer reviewed.

This article is made freely available for use in accordance with BMJ's website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.



To cite Aries P, Iking-Konert C. *Ann Rheum Dis* Epub ahead of print: [please include Day Month Year]. doi:10.1136/annrheumdis-2020-218400

Received 24 June 2020

Accepted 26 June 2020

Ann Rheum Dis 2020;**0**:1. doi:10.1136/annrheumdis-2020-218400

ORCID iD

Christof Iking-Konert <http://orcid.org/0000-0002-8716-3894>

REFERENCES

- Gianfrancesco M, Hyrich KL, Al-Adely S, *et al.* Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry. *Ann Rheum Dis* 2020;79:859–66.
- Available: <https://www.hamburg.de/corona-zahlen>